2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.

Florian ScottéLee SchwartzbergHirotoshi IiharaMatti AaproRichard GrallaPaul J HeskethKarin JordanRonald ChowJørn Herrstedt

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)

This antiemetic MASCC-ESMO guideline update includes new recommendations considering individual risk factors and the optimization of supportive anti-emetic treatments.

Keyphrases

clinical practice
risk factors
chemotherapy induced